;
Home | News & Events

NEWS, OPINION AND EVENTS

Keep up to date with life at the Babraham Research Campus. Explore the latest news, opinion and events from the campus, our stakeholders, partners and the companies based here.

Latest News

10/09/2020

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

Bicycle Therapeutics today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research. 

Read more

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

10/09/2020

Bicycle Therapeutics today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research. 

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy

09/09/2020

We are delighted to announce that we have entered into partnership with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, to explore new treatment options for people with epilepsy.

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement

09/09/2020

PhoreMost and XtalPi Inc today announced they have entered into a drug discovery collaboration agreement. 

Atelerix awarded Innovate UK funding

09/09/2020

Atelerix has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. Funding will be used to explore scalable methods of human cell preservation, transport, and re-presentation for clinical applications.

Ablatus wins £1.4m for technology to blitz tumours

07/09/2020

Addenbrooke’s Hospital in Cambridge will host the first clinical study into a novel technology designed to remove tumours without major surgery.

Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

01/09/2020

Bicycle Therapeutics today announced that the first patient has been dosed in Oxurion’s Phase II study of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME).

Cambridge entrepreneur and investor has been announced as a winner in the regional stage of the Barclays’ Entrepreneur Awards

01/09/2020

Barclays’ Entrepreneur Awards highlight and recognise entrepreneurs who are transforming their industries, the economy and society. Dr Andy Richards, CBE, has received the accolade in the Icon category which seeks to recognise entrepreneurs who have successfully turned their vision into reality.

First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency

01/09/2020

Z Factor Ltd announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD). AATD is a common genetic disorder, affecting around in 1 in 2000 people in Western countries.

Atelerix Consortium Awarded £267,000 Innovate UK Grant

01/09/2020

Atelerix today announces that it has been awarded a grant of £267,000 from Innovate UK, the UK’s innovation agency, with collaborators Rexgenero and the Cell and Gene Therapy Catapult.

Reflection Therapeutics secures co-funding from Innovate UK for major research programme to fight motor neurone disease through cell therapy

13/08/2020

Reflection Therapeutics, Cambridge-based developer of cell therapy against neuroinflammation, is pleased to announce the start of a major Innovate Smart Grant project co-funded by Innovate UKthe UK’s innovation agency.

Bicycle Therapeutics Appoints Dr. Dominic Smethurst as Chief Medical Officer

11/08/2020

Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical Officer.

Decoding cell programming

05/08/2020

Bit Bio has partnered with the London Institute for Mathematical Sciences on a moonshot mission to create every human cell type for use in biomedical research.

Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

05/08/2020

Bicycle Therapeutics today reported financial results for the second quarter ended June 30, 2020 and discussed recent corporate updates.

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

05/08/2020

Spring Bank Pharmaceuticals and F-star Therapeutics today announced that the companies have entered into a definitive share exchange agreement.

Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners

30/07/2020

Abzena has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.

Closed Loop Medicine secures £250,000 Innovate UK continuity funding

30/07/2020

Closed Loop Medicine has secured £250,000 from Innovate UK to support clinical evaluation of a drug + digital combination product for hypertension and COVID- 19 monitoring.

Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration

24/07/2020

F-star Therapeutics Ltd today announces further progress in its long-standing immuno-oncology collaboration with Merck KGaA, Darmstadt, Germany.

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

24/07/2020

Sphere Fluidics today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. 

Stemnovate creates rapid detection kit for Covid-19

21/07/2020

The Babraham Research Campus-based molecular biology and microengineering company says the kit overcomes the drawbacks with current PCR-based testing and offers an economical solution suitable for deployment at businesses, care homes, airports and other key locations.

Bit Bio deal gives BioMed Realty full house at Babraham flagship

16/07/2020

US property powerhouse BioMed Realty has completed the lease-up of its landmark scheme at the Babraham Research Campus in Cambridge UK, underlining the strength of the life science cluster.

Closed Loop Medicine boosts team with key appointment of Melissa Strange as Chief Financial Officer

16/07/2020

Closed Loop Medicine, the London-based therapeutics and health tech company strengthens its leadership team with several new appointments including a top finance director.

Mission and Imperial College London Report Potent and Selective Probe for Deubiquitylating Enzyme UCHL1

08/07/2020

Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics, have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB).

Clinical Data Validates BenevolentAI's AI Predicted Hypothesis For Baricitinib As A Potential Treatment For COVID-19

08/07/2020

BenevolentAI today announced the publication of further experimental data in support of its AI-derived hypothesis for baricitinib as a potential treatment for COVID-19 in the Journal: EMBO Molecular Medicine.

Mission Raises $15m and Expands its Relationship with Pfizer

07/07/2020

Mission Therapeutics today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc.

Nemesis Bioscience announces research collaboration with Shionogi

07/07/2020

Nemesis Bioscience Ltd announced today that it had reached an agreement on terms for a two-year research collaboration with Shionogi & Co. Ltd. to further develop Nemesis Transmid Technology© for the treatment and/or prevention of hard-to-treat respiratory infections caused by Pseudomonas aeruginosa.

The Babraham Research Campus: At the forefront in supporting the UK’s bioscience enterprises and the evidence which proves it!

06/07/2020

A new report published in June this year, confirms the Babraham Research Campus as one of the leading lights in the UK when it comes to delivering a supportive ecosystem to enable the commercialisation of life science research.

Atelerix Strengthens Its Leadership Team

01/07/2020

Atelerix announced today that it has significantly strengthened its leadership team with two experienced industry executives, who will help lead Atelerix in implementing its strategy to provide room temperature solutions for the shipping of therapeutic cells in the fast growing cellular therapy market.

Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board

23/06/2020

Bicycle Therapeutics today announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scientific Advisory Board (SAB).

Atelerix expands availability in Asia

17/06/2020

Atelerix are delighted to announce their partnering with key distributors in Asia: Cosmo Bio, Biogenuix and XP Biomed.

New report confirms the Babraham Research Campus at the forefront in supporting the UK’s early-stage bioscience enterprises

16/06/2020

Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.  

Atelerix awarded the US patent to transport cells in hydrogels

10/06/2020

Today Atelerix received an Issue Notification from the US Patent and Trade Mark Office, notifying us of the awarding of the patent pertaining to the TRANSPORT OF CELLS IN HYDROGELS. 

Bit Bio will be exhibiting and presenting at ISSCR 2020

10/06/2020

Bit Bio will be exhibiting and presenting at this years ISSCR Annual Meeting, which gathers the world’s leading scientists, clinicians, business leaders, ethicists, and educators from more than 65 countries. 

Qkine secures £1.5M series A funding from leading life science investors

09/06/2020

Qkine today announced the successful closure of a £1.5M series A investment round to accelerate the global scale-up of its commercial operations and make key hires to its leadership team.

Babraham Research Campus Impact Report

04/06/2020

In 2019, the Campus partners commissioned a report to evidence the impact the Campus has had on science, the economy and society. Click below to download the full Impact Report.

VisusNano awarded over £225,000 by Innovate UK

03/06/2020

VisusNano, a medtech company developing a biodegradable intraocular lens that can release drugs directly into the eye, has been awarded just over £225,000 by Innovate UK.

Mission Moves to New Babraham Campus Headquarters

03/06/2020

Mission Therapeutics today announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.

Bicycle Therapeutics to Present at Upcoming Investor Conferences

28/05/2020

Bicycle Therapeutics today announced that management will participate in fireside chats at two virtual investor conferences in June.

Bicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics

15/05/2020

Bicycle Therapeutics today announced that a research paper describing the mechanism of action for the Company’s first second-generation Bicycle Toxin Conjugate (BTC), BT5528, has been published in the American Association for Cancer Research (AACR) journal Molecular Cancer Therapeutics.

Closed Loop Medicine partners with US trial to find COVID-19 and hypertension link

15/05/2020

Closed Loop Medicine, a UK therapeutics company, will launch clinical trials in the US to find links between Covid-19 and hypertension.

Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic

06/05/2020

Crescendo Biologics today announce a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody® immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.

Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab

06/05/2020

Bicycle Therapeutics today announced that the first patient has been dosed in a Phase I dose escalation of BT5528 in combination with nivolumab. 

Eisai pledges its support for the Babraham Research Campus’ Accelerate@Babraham initiative

27/04/2020

The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. 

Bicycle Therapeutics Appoints Zafar Qadir as General Counsel

23/04/2020

Bicycle Therapeutics today announced the appointment of Zafar Qadir as the Company’s General Counsel.

MicrofluidX raises £1.4m in seed funding to develop novel cell therapy bioprocessing technology

20/04/2020

MicrofluidX announces it has raised £1.4m in seed funding from leading seed investors UK Innovation & Science Seed Fund (UKI2S), Longwall Ventures and Moulton Goodies Limited with angel contributions from 88 Capital and Cambridge Angels.

F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research

16/04/2020

F-star Therapeutics Ltd today announces the publication of preclinical data on the potent anti-tumor activity of FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40, in leading peer-reviewed journal Cancer Immunology Research.

Biotech rises to COVID-19 testing challenge

07/04/2020

A drug discovery business has announced that it will soon be able to complete 15,000 COVID-19 diagnostic tests per month in a bid to help the country combat the virus.

Start ups the rock stars of our generation

06/04/2020

The second life science bio-incubator programme on Campus ended on a high for its participants as they presented their science and achievements to a distinguished audience.

Bicycle Therapeutics to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Conference

06/04/2020

Bicycle Therapeutics today announced that management will participate in a panel discussion on bispecifics at the Canaccord Genuity Horizons in Oncology Conference.

Two startups share LifeArc ‘Accelerate’ Award

18/03/2020

Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures within the active Babraham Research Campus community.

BenevolentAI analyses approved drug as potential Covid-19 treatment

12/03/2020

BenevolentAI has used artificial intelligence to identify and analyse an approved drug that may have potential as a coronavirus treatment.

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

10/03/2020

Bicycle Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2019 and discussed recent corporate updates.

The end of this year’s Accelerate@Babraham programme doesn’t necessarily mean the end of the journey at the Babraham Research Campus for the winning start-ups

10/03/2020

After spending five-months on Campus the five winning StartUP@Babraham competition start-ups have come to the end of the programme. But for some, their journey at the Babraham Research Campus has only just begun.

LifeArc ‘Accelerate@Babraham Award’ for most progressed venture awarded to CC Bio and Reflection Therapeutics

05/03/2020

Introduced by the Babraham Research Campus in 2018, the Accelerate@Babraham initiative supports ambitious early stage life science ventures within the active Babraham Research Campus community.

PolyProx Therapeutics raises an additional £1 million seed financing from new investor LifeArc

03/03/2020

PolyProx Therapeutics today announces that it has raised an additional £1 million seed capital from new investor, LifeArc, to validate polyproxin® drug leads in oncology.

Bit Bio Secures Distribution Agreement with Abcam to Democratize Access to Human Cells for Global Life Science Research

03/03/2020

Bit Bio announces agreement with Abcam to make Bit Bio's iPSC derived functional human cells widely available to the global life science community.

Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech

25/02/2020

Bicycle Therapeutics today announced that it has entered into a strategic collaboration agreement with Genentech to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies.

BenevolentAI announces scientific collaboration with UC San Diego to investigate Cerebral Cavernous Malformations

20/02/2020

Joint partnership will focus on developing a therapy for CCM - a highly rare disease that currently has no effective treatment.

Analysis of RNA sequences and modifications by mass spectrometry published in Nature Communications

20/02/2020

STORM Therapeutics today announces that it has published a scientific paper in the peer reviewed journal Nature Communications.

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics

20/02/2020

Sphere Fluidics today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing.

Public Art Installation: Tree Planting

18/02/2020

As a condition of the outline planning consent underpinning the BioMed@Babraham buildings, provision has been made on Campus for the installation of a permanent, publicly accessible artwork, which those on Campus and the local Babraham community can interact with and enjoy.

F-star Therapeutics Announces FDA Acceptance of IND Application for FS120

11/02/2020

F-star Therapeutics today announces that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for FS120, F-star’s proprietary tetravalent bispecific antibody targeting CD137 and OX40.

PhoreMost strengthens leadership team with two key appointments

11/02/2020

PhoreMost Limited today announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.

Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer

11/02/2020

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted, T cell enhancing therapeutics, today announces the appointment of Dr Kenji Hashimoto asthe Company’s Chief Medical Officer (CMO).

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

10/02/2020

Benevolent AI have used their knowledge graph to identify a potential treatment for coronavirus.

RxCelerate takes 25,000 sq ft at Cambridge bio hub

27/01/2020

Expanding life sciences business RxCelerate is moving its Cambridge HQ by taking 25,000 sq ft of prime office and lab space at BioMed Realty’s flagship research development at Babraham Research Campus.

PredictImmune announces commercial partnership with Cambridge Clinical Laboratories (CCL)

21/01/2020

PredictImmune today confirmed that it has entered into a commercial agreement with CCL, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK, Ireland (non-exclusive), the Middle East and the Balkans (exclusively).

F-star Therapeutics Appoints Dr. Edward Benz and Mr. Geoff Race to Board of Directors

15/01/2020

F-star Therapeutics today announces the appointments of Dr. Edward Benz and Mr. Geoff Race to its Board of Directors, further strengthening the depth and breadth of its clinical and industry expertise.

Ablatus Therapeutics achieves ISO 13485:2016 certification

15/01/2020

Ablatus has been certified to ISO 13485:2016 following successful audits with BSI.

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

09/01/2020

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim’s discovery programmes.

Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401

07/01/2020

Bicycle Therapeutics today announced a second collaboration with Cancer Research UK in which Cancer Research UK will fund and sponsor development of BT7401.

PredictImmune PROFILE trial recruits over 200 patients

07/01/2020

PredictImmune is pleased to confirm that its PROFILE trial has reached the half way mark in terms of recruitment, having secured over 200 patients.

LifeArc ‘Accelerate@Babraham Award’ will give one early-stage life science venture additional cash boost

06/01/2020

Sponsors of the Babraham Research Campus Accelerate@Babraham initiative, LifeArc, has announced the extension of its support, by releasing an additional £10,000 in the form of an award for the most progressed venture.

Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

26/11/2019

Bicycle Therapeutics today announced that management will present in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. ET in New York.

Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

18/11/2019

Bicycle Therapeutics today announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 2:40 p.m. GMT (9:40 a.m. ET) in London, England.

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumours

18/11/2019

Bicycle Therapeutics today announced that the first patient has been dosed in the Phase I dose escalation of its Phase I/II study of BT5528, a BicycleToxin Conjugate (BTC) targeting tumour antigen EphA2, in patients with advanced solid tumours associated with EphA2 expression. 

Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update

07/11/2019

Bicycle Therapeutics today reported financial results for the third quarter ended September 30, 2019 and discussed recent corporate updates.

Bicycle Therapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting

31/10/2019

Bicycle Therapeutics today announced that new preclinical data from BT7480, a potent tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), will be presented at the Society for Immunotherapy of Cancer’s (SITC) 2019 Annual Meeting.

Bicycle Therapeutics Announces Appointment of Veronica Jordan, Ph.D., to Board of Directors

31/10/2019

Bicycle Therapeutics today announced the appointment of Veronica Jordan, Ph.D., to its Board of Directors, where she will serve as Chair of the Compensation Committee. 

Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer

29/10/2019

Bicycle Therapeutics today announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone. Dr. Crockett has more than 25 years of experience in global business development for biopharmaceutical companies.

Meet Ashok at EMNLP for an oral presentation about his latest paper co-authored with Sia Togia

18/10/2019

Meet Ashok, researcher at BenevolentAI, at EMNLP for an oral presentation about his latest paper co-authored with Sia Togia: Biomedical relation extraction with pre-trained language representations and minimal task-specific architecture.

Abzena Names Kimball Hall as Chief Operating Officer

18/10/2019

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team.

Induction Day with Cambridge Life-Science Cluster Vanguards for Accelerate@Babraham 2019 Winners

04/10/2019

The Babraham Research Campus has welcomed the second group of start-ups to its Accelerate@Babraham competition programme with a day of networking and a stellar cast of guest speakers.

Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress

30/09/2019

Bicycle Therapeutics today announced the presentation of updated data from a Phase I/IIa trial conducted in collaboration with Cancer Research UK and evaluating BT1718 in an unselected group of patients with advanced solid tumours.

Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial at ESMO 2019 Annual Congress

24/09/2019

Bicycle Therapeutics plc today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evaluating the Company’s lead asset BT1718 in patients with advanced solid tumors will be presented at the European Society of Medical Oncology (ESMO) 2019 Annual Congress. 

Accelerate@Babraham attracts additional sponsorship to boost innovation in Cambridge life science cluster

23/09/2019

LifeArc joins AstraZeneca in providing funding towards the continued development of the Babraham Research Campus’ Accelerate@Babraham initiative.

Babraham Research Campus companies represented in Cambridge Independent Science and Technology Awards shortlisting

13/09/2019

The shortlist represents a showcase of the enormous talent in the Cambridge region across sectors from biotech to cleantech, artificial intelligence to agritech including companies from Babraham Research Campus.

BenevolentAI announces Agreement with leading healthcare company to leverage BenevolentAI’s technology platform

13/09/2019

BenevolentAI today announced that it has signed a Framework Collaboration Agreement with Novartis Pharma AG (“Novartis”) to leverage BenevolentAI’s technology platform to interrogate clinical trial and experimental data.

Benevolent AI‘s Dr Jackie Hunter discusses defining innovation

21/08/2019

Benevolent AI’s Dr Jackie Hunter (CE Clinical & Strategic Partnerships) debates the culture of innovation, how to define, approach and measure it in interview with IDEA Pharma.

An Interview With Dr. Daniel Ives of Shift Bioscience

09/08/2019

Shift Bioscience is a company aiming to solve the problem of mitochondrial dysfunction, one of the hallmarks of aging, by repairing the aging mitochondria in our cells so that they work as if they were younger.

Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update

08/08/2019

Bicycle Therapeutics plc, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.

Bicycle Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

01/08/2019

Bicycle Therapeutics plc, today announced that management will present at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 at 1:30 p.m. EDT in Boston, MA.

Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

23/07/2019

Abzena announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). 

A whole new therapeutic area is taking medical research by storm

05/07/2019

Babraham Research Campus based Storm Therapeutics is leading the development of the first treatments to target a new layer of genetic information encoded in the RNA.

Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

27/06/2019

Abzena announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO).

Accelerate@Babraham Start-up Competition 2019: Winners Announced

21/05/2019

Five science start-ups have been awarded £10k, access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham, and an extended programme of mentoring and support.

Babraham Research Campus ready for pitching bonanza

13/05/2019

The Campus is going to be busy on Wednesday (May 15), with the one-day Babraham Investor Conference (BIC) immediately followed by the Accelerate@Babraham pitches, which gives five organisations the chance to work at Babraham for five months.

AstraZeneca and BenevolentAI team up to fight chronic kidney disease and idiopathic pulmonary fibrosis

07/05/2019

A long-term collaboration between AstraZeneca and BenevolentAI will bring the power of artificial intelligence and machine learning to bear in the hunt for new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.

Cambridge biotech luminaries deliver masterclass on hiring and investment

22/11/2019

Our winning Accelerate@Babraham start-ups benefit from the experience of two of the most prominent biotech names in the Cambridge life science cluster - Dr Jane Osbourn and Dr Andy Richards.

Bridging the Innovation Gap with AI

18/10/2019

Chief Executive of Clinical and Strategic Partnerships at BenevolentAI Dr Jackie Hunter writes a piece for Pharma Boardroom on why the pharmaceutical industry has been slow to adopt artificial intelligence-based technologies and also makes a prediction for the industry’s future.

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

18/10/2019

Chipscreen Biosciences and Novogene recently announced a strategic partnership for companion diagnostics (CDx) development. 

BioMed Realty announces first lettings at Babraham Research Campus in Cambridge

17/10/2019

Today, BioMed Realty, the leading provider of real estate solutions to the life science community, announced its two newly developed Babraham Research Buildings in Cambridge are more than 50% let or under offer, including leases to PetMedix Ltd and Mission Therapeutics Ltd.

Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute

22/10/2019

Bicycle Therapeutics today announced that it will collaborate with Oxford University’s Oxford Drug Discovery Institute (ODDI) to use Bicycle® technology for the development of novel therapeutics for dementia.

The Medicine Maker 2019 Power List

25/04/2019

Benevolent AI‘s Prof Jackie Hunter, Director, featured as a Champion of Change in The Medicine Maker 2019 Power List.

Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

01/04/2019

Dr. Smith will assume responsibility for leading Artios's overall preclinical and clinical development strategy, regulatory, and medical activities.

Abzena Announces New Fully Integrated Developability and Optimization Service

21/03/2019

Abzena announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service.

Apply to present at the 2019 Babraham Investor Conference

18/03/2019

The Babraham Investor Conference (BIC) is back to bring together like-minded investors focussed on early-stage and scale-up life science and med-tech opportunities.

Applications now open for the second Accelerate@Babraham life-science start-up competition

06/03/2019

The annual competition gives up to five ventures the opportunity to win access to facilities, and take part in a fast-paced programme of support, led by a hand-picked group of experienced academic and commercial life science experts.

Babraham Bioscience Technologies announce new Board Member

18/02/2019

The Board of Babraham Bioscience Technologies (BBT) welcomes Dr Karen Lewis as Non-Executive Director.

Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

11/02/2019

In an exceptional career in Pharmaceutical R&D Professor Chopra has held a number of distinguished roles, and has now been appointed as Non-Executive Director of Artios Pharma.

Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial

01/07/2019

Bicycle Therapeutics today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME). 

Bicycle Therapeutics Announces Pricing of Initial Public Offering

23/05/2019

Bicycle Therapeutics, who are pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the pricing of its initial public offering in the United States.

Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund

07/05/2019

Bicycle Therapeutics today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases.

Bicycle Therapeutics Awarded £496,000 (US $640,000) SBRI Contract to Address Antimicrobial Resistance in Humans

12/02/2019

Bicycle Therapeutics announces it has been awarded a contract from the Department of Health and Social Care as part of the Small Business Research Initiative.

Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman

18/03/2019

Bicycle Therapeutics announced today the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors.

Bicycle Therapeutics Strengthens Clinical Team to Advance Expanding Pipeline

09/05/2019

Bicycle Therapeutics today announced two senior appointments to facilitate its expanding and advancing clinical pipeline.

Bicycle Therapeutics Strengthens Executive Team with Key Changes

20/02/2019

Bicycle Therapeutics today announced several key changes to its executive team, including the appointment of Peter B. Leone as Chief Business Officer and the promotion of Lee Kalowski, Chief Financial Officer, to the role of U.S. President.

Bicycle Therapeutics to Present at ELRIG’s Research & Innovation 2019 Conference

02/04/2019

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that Paul Beswick, Ph.D., Bicycle’s Director of UK Chemistry and IP, will present at the Research & Innovation 2019 conference.

Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumor-targeted Bispecific Bicycles at Peptides Congress

24/04/2019

Bicycle Therapeutics announced today that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will present at the 6th Annual Peptides Congress in London.

Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumors, at World ADC 2019

05/03/2019

Bicycle’s Director of Preclinical Development and Project leader for BT5528, will present at the 9th Annual World ADC Conference in London. 

Bicycle Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting

29/03/2019

Bicycle Therapeutics announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.

Business Weekly New Year Honours 2019

17/01/2019

Business Weekly has announced its New Year Honours 2019. Find out where Babraham Research Campus was listed below.

Closed Loop Medicine receives major InnovateUK grant award for hypertension clinical programme

23/07/2019

Closed Loop Medicine raises £1.3 million in research grant funding through the InnovateUK Innovation Accelerator, Longwall Ventures and IQ Capital.

Conferencing and Events team shortlisted for top industry award

05/09/2019

The Conferencing and Events team at the Babraham Research Campus is delighted to have made the shortlist for 2019’s miaList which honours the industry’s greatest talents.

Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer

13/09/2019

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announces that Stewart Kay has been appointed as the Companys Chief Business Officer (CBO).

Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda

31/07/2019

Crescendo Biologics Ltd (Crescendo) announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised a second option under its existing, multi-target collaboration and license agreement.

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

01/05/2019

Mission Therapeutics today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect.

Dutch specialist buys Cambridge science building

08/04/2019

Dutch property investor and developer Kadans Science Partner has taken its first step into the Cambridge and UK life science market by acquiring a major building on the Babraham Research Campus from Imperial College ThinkSpace.

F-star appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA

20/06/2019

F-star Therapeutics Ltd today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.

F-star appoints Dr Louis Kayitalire as Chief Medical Officer

12/06/2019

F-star today announces the appointment of Louis Kayitalire, MD, as Chief Medical Officer (CMO), which will be effective on 17 June 2019.

High-speed drama for Accelerate@Babraham pitches

28/05/2019

The second Accelerate@Babraham start-up competition final at the Babraham Research Campus proved even more full-throttle than the first.

Human Developmental Biology Initiative announced

31/07/2019

Institute researchers are part of a world-first research project that will unravel how human embryos develop in the first weeks and months after fertilisation, improving our understanding of fertility, birth defects and regenerative medicine.

ImmBio signs deal with CNBG in China to develop pneumococcal disease vaccine

24/03/2019

ImmBio’s PnuBioVax vaccine aims to be the first vaccine targeting all S. pneumoniae variants, and offers the potential to tackle the antibiotic resistance problem at its source.

Innovation Seminar: Bioassay Development and Immunogenicity Testing in a Regulated Environment

30/09/2019

This event is mainly targeting protein and antibody researchers, bioanalysis research scientists and research groups with an interest in precision medicine, translational oncology and biomarkers.

Investors invited to discover the next big thing in life science and med-tech

25/03/2019

Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.

Kymab Appoints Catherine Moukheibir as Non-Executive Director

16/07/2019

Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, announces the appointment of Catherine Moukheibir as a Non-Executive Director.   

Kymab appoints Simon Sturge as Chief Executive Officer

08/04/2019

Kymab today announced the appointment of Simon Sturge as its new CEO, effective May 1, 2019. Simon succeeds David Chiswell, who remains a scientific adviser to the Company.

LifeArc takes $30m equity stake in Kymab, gains access to antibody tech

27/06/2019

UK medical research charity LifeArc is to take a $30m equity stake in biotech company Kymab, and will access its antibody platform to further its drug discovery efforts.

Lucy Cavendish welcomes new members to the Fellowship

09/12/2019

BBT CEO Derek Jones named as new Fellow of Lucy Cavendish College, University of Cambridge.

Magdalene Boat Club Signs Up High-Growth Local Drug Developer RxCelerate as Headline Sponsor on a Five-Year Deal

12/06/2019

Magdalene Boat Club announced today that it had signed a sponsorship agreement with RxCelerate.

ManChem funding roundup

22/05/2019

Atelerix Ltd, creator of an innovative cell encapsulation technology, has closed a second round of funding of £700,000 (US$893,000) to accelerate the development of its cell transport products to market.

Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters

23/07/2019

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund. 

Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone

06/12/2019

Mission Therapeutics and AbbVie today announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration.

More than £16 million Innovate UK and private equity investment into companies confirmed

09/08/2019

More than £16 million Innovate UK and private equity investment into companies across the UK developing new precision medicine technologies has been confirmed including Closed Loop Medicine.

Mote Research secures an Innovate Smart Grant

01/10/2019

Mote Research is delighted to announce that it has secured an Innovate Smart Grant. This grant will fund a £0.5M project to further develop and test Mote’s therapeutic genome editing technology. 

NEMESIS BIOSCIENCE WINS INNOVATE UK SBRI FUNDING AWARD

27/03/2019

Nemesis Bioscience has been successful in winning a £414, 000 award granted by the UK’s innovation agency, Innovate UK.

NeoPhore appoints Dr John Haurum as Non-Executive Director

20/03/2019

NeoPhore Limited, a cancer
immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect.

NICE issues Medtech Innovation Briefing on PredictSURE IBD™ for inflammatory bowel disease prognosis

28/03/2019

PredictImmune today announced that the UK's National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of PredictSURE IBD™ in the prognosis of inflammatory bowel disease.

Open data: tech companies seek better licences

06/12/2019

With the growing popularity of data development in the open source space, counsel at Red Hat, Microsoft and Benevolent AI say a mechanism is needed to enable better collaboration.

PATIENTS SUGGESTION LEADS TO NEW BRITISH COMPANY DEVELOPING THE WORLD’S FIRST ‘HOME USE’ BLOOD POTASSIUM TEST KIT

26/06/2019

A fast, accurate and low-cost test for blood potassium levels, which can be used at home and has the potential to improve the safety, health and lifestyle of tens of millions of people worldwide, is being developed by Kalium Diagnostics.

PhoreMost and inStem enter structural biology alliance

09/07/2019

PhoreMost today announced it has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.

PhoreMost and Sentinel extend cancer collaboration

18/11/2019

PhoreMost and Sentinel Oncology have expanded a collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of Glioma.

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director

16/07/2019

PhoreMost today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director.

PhoreMost unveils plans for Series B and fresh spin-outs

26/06/2019

PhoreMost is set for a transformative phase of expansion that will create a revolutionary drug discovery business capable of influencing new treatments across a range of disease areas and featuring some of the world’s most influential Pharma players.

PolyProx Therapeutics raises £3.4m seed financing to validate novel class of drugs to treat cancer

30/04/2019

PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.

PredictImmune and the Crohn’s & Colitis Foundation announce start of jointly-sponsored study to validate PredictSURE IBD™

07/11/2019

PredictImmune today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.

PredictImmune announce formal entry of PredictSURE IBD™ into the NICE Diagnostic Assessment Programme

12/03/2019

The DAP evaluates new, cutting-edge medical diagnostic technologies, producing guidance to help people working in the NHS make efficient, cost-effective and consistent decisions about adopting new products.

PredictImmune announce issuance of new patent in the US in support of commercialisation

26/02/2019

PredictImmune today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property relating to methods for predicting autoimmune disease risk.

PredictImmune announces a strategic agreement with Theradiag

29/10/2019

PredictImmune announces a strategic agreement with Theradiag for French speaking Europe to commercialise PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease.

PredictImmune announces new strategic partnership to commercialise its PredictSURE IBD™ prognostic test

22/10/2019

PredictImmune today confirmed that it has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to commercialise and provide PredictImmune’s prognostic test for inflammatory bowel disease (IBD), PredictSURE IBD™, throughout North America.

PredictImmune announces new ‘framework agreement’ with Cambridge Enterprise

19/09/2019

The agreement will allow future expansion of original IP license to expand its commercial product pipeline; extending the benefits of prognostic testing to include systemic lupus erythematosus (SLE).

PredictImmune appoints Steven S. Martin as non-executive director

05/11/2019

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Steven S. Martin to its board.

 

PredictImmune appoints Tim Rea of BGF as non-executive director

20/08/2019

PredictImmune is delighted to welcome Tim Rea, an experienced entrepreneur and investor at BGF, to its board.

PredictImmune closes Series B funding round, raising £10M to further accelerate global commercial expansion and support expanding product pipeline

30/07/2019

PredictImmune today announced the completion of its Series B funding having raised £10M.

PredictImmune confirms Canadian patent grant

24/01/2019

PredictImmune today confirmed its latest patent grant in Canada.

PREDICTIMMUNE MAKES FURTHER STRIDES TOWARDS JANUARY LAUNCH OF PREDICTSURE IBD™, BY GAINING ISO 13485 MEDICAL DEVICES CERTIFICATION

18/12/2018

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced confirmation of its ISO 13485 certification.

PredictImmune pleased to announce the appointment of James Clark as Chief Technology Officer

18/11/2019

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome James Clark as Chief Technology Officer.

PredictImmune wins Business Weekly Life Science Innovation (Product) award

21/03/2019

PredictImmune is delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.

PredictImmune’s first prognostic test for IBD, PredictSURE IBD™, launches in the UK and Ireland

02/04/2019

PredictImmune today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.

Qkine secures additional £550K funding

03/06/2019

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

RNA Epigenetics in Human Disease Conference

31/07/2019

STORM Therapeutics' RNA Epigenetics in Human Disease Conference will take place 17th-20th September.

RNA proximity sequencing reveals the spatial organisation of the transcriptome in the nucleus

16/07/2019

Sphere Fluidics are proud to be involved in study where Proximity RNA-seq was used to understand the spatial organisation of RNA molecules in the nucleus.

The Babraham Research Campus accelerator programme attracts further sponsorship to support early-stage science ventures

11/11/2019

With the second wave of its ‘Accelerate@Babraham’ life sciences bio-incubator programme well underway, the Babraham Research Campus has confirmed additional financial and mentoring support for the initiative from Mundipharma.

Rob Treanor joins Sphere Fluidics as Director of Operations and Andrew Campbell as Director of Finance

26/03/2019

Sphere Fluidics announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites.

 

Sanj Kumar joins Atelerix as Chief Business Officer

28/11/2019

Atelerix announced today that it has significantly expanded and strengthened the commercialisation of its innovative product range by hiring industry expert Sanj Kumar as its Chief Business Officer.

Science awards shortlist highlights talent and achievements at the Babraham Research Campus

19/09/2019

Babraham-based companies prominent in biotech, life science and innovation categories.

Sphere Fluidics closes $2m (£1.5m) investment round

29/01/2019

Sphere Fluidics announced today that it has closed a $2 million (circa £1.5 million) investment round.

Sphere Fluidics closes a $4.8 million USD (£3.7 million) Funding Round

12/06/2019

Sphere Fluidics announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment.

Sphere Fluidics hits a fresh Peak with cell analysis collaboration

18/11/2019

Sphere Fluidics, which is commercialising single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation which supplies intelligent lab automation solutions, have announced a cell analysis collaboration.

Start Codon founded in Cambridge, UK, to deliver premier life science and healthcare business acceleration program

23/04/2019

Start Codon has been launched with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.

Start Codon strengthens senior team with key appointments

16/07/2019

Start Codon announced today two appointments to its senior team. Daniel Rooke has joined as Partner and Head of Operations, and Sakura Holloway as Partner and Head of Diligence.

What the Cambridge & Peterborough Local Industrial Strategy means for Life Sciences

21/08/2019

One Nucleus CEO Tony Jones examines what the Cambridge and Peterborough Local Industrial Strategy means for life sciences.

Studying our ageing immune system with help of Cambridge BioResource

16/07/2019

The study of how our immune system changes as we age has been aided by volunteers in the Cambridge BioResource.

Wall Street warms to Bicycle history makers

09/07/2019

Therapeutics powerhouse Bicycle is a history-maker in the sphere of life sciences. It can justifiably claim to be the first company to be headquartered in Cambridge at the time of an IPO on the NASDAQ technology market in the US.

Validating innovative solutions in cell biology

09/07/2019

A case study from Aureliabio using Atelerix Ltd innovative technology for room temperature preservation of cells and tissues.

The winning formula behind Cambridge’s Silicon Fen success story

05/07/2019

William Wallis, UK Correspondent at the FT explores how collaboration between academics and entrepreneurs over 30 years has transformed the Cambridge region.

STORM Therapeutics Appoints Dr John Haurum to the Board of Directors

27/06/2019

STORM Therapeutics today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

STORM Therapeutics extends Series A to GBP 30M (USD 38.43M) with new investor, Seroba Life Sciences

22/05/2019

STORM Therapeutics today announced that it has raised an additional £14 million bringing the total Series A financing to £30 million.

The academic founders' conundrum

25/04/2019

Tony Kouzarides spoke to BioCentury about co-founding Storm Therapeutics and how academics connect with the biotech industry to build companies.

Theodora Harold to be appointed new CEO at Crescendo Biologics

04/04/2019

Crescendo Biologics Ltd (Crescendo) today announces that Theodora Harold will be appointed as CEO. She will be succeeding Peter Pack who will be stepping down from the position of CEO on 1 May 2019.

Presentation day showcases success of Accelerate@Babraham start-up competition

23/12/2018

The first ever life science bio-incubator programme competition at the Babraham Research Campus, Accelerate@Babraham, has ended on a high for the competition winners with the promise of ongoing mentoring and an invitation to present at the renowned Babraham Investor Conference in 2019.

PredictImmune awarded Innovate UK grant to apply its biomarker-based technology towards the prediction of drug response in IBD

14/12/2018

PredictImmune, developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded a grant of £100,000 by Innovate UK, the UK’s innovation agency. 

PredictImmune’s first prognostic test, PredictSURE IBD™, set for UK and European launch having been awarded CE mark

11/12/2018

PredictImmune today announced CE IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification for its prognostic biomarker test for IBD, PredictSURE IBD- the first validated biomarker based prognostic test in inflammatory disease.

Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

07/12/2018

Mission Therapeutics has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect.

PredictImmune and the Crohn’s & Colitis Foundation announce a joint study to validate and prove efficacy of first prognostic test for IBD in the US market

04/12/2018

PredictImmune today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.

BICYCLE THERAPEUTICS TO PRESENT AT 30TH ANNUAL PIPER JAFFRAY HEALTHCARE CONFERENCE

27/11/2018

Bicycle Therapeutics announced today that management will present a company update at the 30th Annual Piper Jaffray Healthcare Conference.

BICYCLE THERAPEUTICS NAMED BEST NEW DRUG DEVELOPER AT 2018 WORLD ADC AWARDS

14/11/2018

Bicycle Therapeutics today announced that it has been recognized at the 2018 World ADC Awards, held during the World ADC Conference in San Diego, Calif., as Best New Drug Developer.

BICYCLE THERAPEUTICS’ FOUNDER SIR GREGORY WINTER TO DELIVER KEYNOTE ADDRESS AT THE 2018 PROTEIN AND ANTIBODY ENGINEERING (PEGS) SUMMIT EUROPE

13/11/2018

Additional company presentation will highlight preclinical research supporting the development of CD137 Bicycle® agonists as novel cancer immunotherapies.

BICYCLE THERAPEUTICS TO PRESENT AT JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE08

08/11/2018

Bicycle Therapeutics announced today that management will present a company update at the Jefferies 2018 London Healthcare Conference.

PREDICTIMMUNE ANNOUNCES NEW PATENT GRANTS AND ALLOWANCES ACROSS THE UK, EU AND CANADA

18/10/2018

PredictImmune announced today the granting of patents in the UK and Europe and Notice of Allowance in Canada relating to a method for predicting autoimmune disease risk.

ACCELERATE@BABRAHAM INTAKE LEARNS HOW TO WALK THROUGH WALLS

04/10/2018

A memorable induction for the first-ever Accelerate@Babraham competition winners cohort included masterclasses from two of Cambridge’s most spectacularly successful entrepreneurs and investors, Andy Richards and Jonathan Milner.

PredictImmune invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit

03/10/2018

PredictImmune announced today that it has been invited to present at the Crohn’s & Colitis Foundation IBD Biomarkers Summit in October 2018.

ACCELERATE@BABRAHAM ATTRACTS ADDITIONAL SUPPORT FROM TAYLOR VINTERS AND SILICON VALLEY BANK

10/09/2018

International law firm and technology focused banking group confirm support for Accelerate@Babraham’s inaugural programme.

ABZENA ACQUIRED BY ASTRO BIDCO LIMITED, A NEW COMPANY WHOLLY-OWNED BY THE WCAS FUND IN NEW YORK

17/08/2018

The Big Apple has taken another bite out of Cambridge UK biotech with a near-$44 million acquisition of Abzena by a newly-formed New York enterprise. 

ACCELERATE@BABRAHAM START-UP COMPETITION: WINNERS ANNOUNCED

13/07/2018

Five science start-ups have been awarded £20k and access to the Babraham Research Campus bio-incubator facilities, Accelerate@Babraham.

PREDICTIMMUNE APPOINTS NEW CEO

02/07/2018

PredictImmune, a developer of pioneering prognostic products for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the appointment of Paul Kinnon as its new Chief Executive Officer.

HOW UK LIFE SCIENCES WILL TRANSFORM OUR LIVES

26/06/2018

Taylor Vinters is an international law firm supporting the businesses which drive the innovation economy, and the entrepreneurs and private wealth that underpin them.

SHIONOGI INVESTS IN NEMESIS TECHNOLOGY

19/06/2018

Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience. Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M.

THE BABRAHAM RESEARCH CAMPUS LAUNCHES START-UP COMPETITION FOR THE CHANCE TO ACCESS ITS LIFE SCIENCE BIO-INCUBATOR, ACCELERATE@BABRAHAM

29/05/2018

Life science start-ups are invited to apply for one of up to five prizes that include a cash prize and access to the Babraham Research Campus bio-incubator facilities and much more...

PREDICTIMMUNE JOIN THE BABRAHAM RESEARCH CAMPUS COMMUNITY

14/05/2018

Developer of pioneering tools for guiding treatment options in immune-mediated inflammatory diseases choose Babraham Research Campus as permanent base within the Cambridge Cluster.

PredictImmune secures £4.3m investment from Wellcome Trust to evaluate the clinical utility of its prognostic test in Crohn’s disease

30/04/2018

PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust.

IMPERIAL COLLEGE THINKSPACE FILLS SPACE AT THE BABRAHAM RESEARCH CAMPUS

17/04/2018

Imperial College ThinkSpace has welcomed two companies, Abzena plc and Bicycle Therapeutics Ltd, into its new 49,500 sqft building (Building 900) at the Babraham Research Campus near Cambridge.

THE BABRAHAM RESEARCH CAMPUS APPOINTS DR KAROLINA ZAPADKA TO LEAD ACCELERATE@BABRAHAM

19/03/2018

The Babraham Research Campus is delighted to announce the appointment of Dr Karolina Zapadka as Business Acceleration Manager for the Babraham Research Campus’ bio-incubator and life science accelerator, Accelerate@Babraham.

Registration now open for Babraham Investor Conference (BIC) 2018

Registration now open for Babraham Investor Conference (BIC) 2018

16/03/2018

Our highly successful annual Investor Conference for investors focusing on early-stage and scale-up life science and med-tech companies seeking Seed to Series C funding returns on the 22nd May.

DEREK JONES JOINS THE REGION'S LIFE SCIENCE & HEALTHCARE MEMBERSHIP ORGANISATION

DEREK JONES JOINS THE REGION'S LIFE SCIENCE & HEALTHCARE MEMBERSHIP ORGANISATION

07/03/2018

One Nucleus is delighted to announce the appointment of Derek Jones as a Non-Executive Director. Derek is Chief Executive of Babraham Bioscience Technologies Ltd (BBT), the organisation responsible for the development and management of the Babraham Research Campus.

New bio-incubator and life-science accelerator capability launches at the Babraham Research Campus

New bio-incubator and life-science accelerator capability launches at the Babraham Research Campus

25/01/2018

Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes (the ‘accelerator’).

Abzena takes on new facilities in Cambridge, UK and San Diego

Abzena takes on new facilities in Cambridge, UK and San Diego

05/01/2018

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.

BBT 'Technology Development Laboratory' (TDL) moves to Abzena

BBT 'Technology Development Laboratory' (TDL) moves to Abzena

05/01/2018

Abzena plc has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).

Bicycle Therapeutics Secures an Innovate UK Grant to Develop Next Generation Antibiotics

Bicycle Therapeutics Secures an Innovate UK Grant to Develop Next Generation Antibiotics

04/01/2018

Bicycle Therapeutics announced today that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.

BioMed@Babraham Partnership Launch

BioMed@Babraham Partnership Launch

20/12/2017

In October 2017, we were delighted to launch our partnership with BioMed Realty. This collaboration will see a new 108,000 square foot scale-up research space for growing bioscience-based companies built on site. Watch the launch video to find out more.

NOVOGENE ESTABLISHES FIRST EUROPEAN GENOMIC SEQUENCING CENTER AT THE BABRAHAM RESEARCH CAMPUS

21/05/2018

Novogene, a leading global provider of genomic services and solutions, today announced its first genomic sequencing center in Europe.

Biosceptre welcomes Tuspark S & T into its Series A fund raising round

Biosceptre welcomes Tuspark S & T into its Series A fund raising round

14/12/2017

Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7.

Bicycle Therapeutics & Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

Bicycle Therapeutics and Cancer Research UK Named Best Partnership Alliance of the Year at 2017 Scrip Awards

06/12/2017

Bicycle Therapeutics and Cancer Research UK today announced that their collaboration has secured a prestigious Scrip Award, winning 2017’s Best Partnership Alliance.

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore

15/12/2017

Sixth Element Capital LLP (6EC), a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund, announces a £3 million investment in NeoPhore Ltd, a spin out from Cambridge, UK based PhoreMost Ltd.

MRC spin out Bicycle Therapeutics announces partnership with AstraZeneca in $1bn deal

MRC spin out Bicycle Therapeutics announces partnership with AstraZeneca in $1bn deal

15/12/2017

In 2016, Bicycle Therapeutics - a MRC spin out company - entered into a collaboration with AstraZeneca potentially worth $1bn.

Crescendo Biologics Shortlisted for ‘Licensing Deal of The Year’

Crescendo Biologics Shortlisted for ‘Licensing Deal of The Year’

01/11/2017

Crescendo Biologics is pleased to announce that it has been shortlisted for ‘Licensing Deal of the Year’ at the Scrip Awards 2017.

Sphere Fluidics' Cyto-Mine wins major European Product Innovation award

Sphere Fluidics' Cyto-Mine wins major European Product Innovation award

01/11/2017

Sphere Fluidics’ proprietary Cyto-Mine® platform can perform multiple tasks in a single compact and portable system, reducing equipment costs and lab space.

Babraham Research Campus announces new life science development

Babraham Research Campus announces new life science development

26/10/2017

New project in grounds of the Babraham Research Campus will enhance Cambridge’s global position in life sciences community.

The only meeting checklist you’ll ever need

The only meeting checklist you’ll ever need

19/10/2017

The events team at Babraham Research Campus has many years of event management experience between them, here they share their knowledge to ensure your next meeting is a success.

How to use social media to make your next event memorable

How to use social media to make your next event really memorable

26/09/2017

We’ve all attended lots of events – training courses, team meetings, conferences – but some will stand out in your mind more than others. Why is this?

Solving the Problem of Scale Up - Babraham Panel Discussion

Solving the Problem of Scale Up - Babraham Panel Discussion

12/07/2017

See highlights of a panel discussion held in The Cambridge Building, which gathered senior key opinion leaders together to discuss the BioMed@Babraham development as well as the life science sector more broadly.

Babraham Research Campus Bennet Building

Babraham Research Campus Bennet Building

23/04/2017

The construction of the Bennet Building at the Babraham Research campus is discussed together with the role of the campus and BBSRC in innovation.

Cambridge Life Sciences

Cambridge Life Sciences

01/04/2017

Babraham Campus CEO Derek Jones leads us through a short history of monoclonal antibody research in the Cambridge life science cluster and asks what the next big thing will be in this area of exciting medical technology.

Bicycle Therapeutics Strengthens Senior Management Team

Bicycle Therapeutics Strengthens Senior Management Team

26/09/2017

Bicycle Therapeutics Strengthens Senior Management Team With Appointment of Maria Koehler, M.D., Ph.D., as Chief Medical Officer.

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

20/09/2017

Evelyn Warner, Editor of LaBiotech.eu, a leading digital media publisher covering the European Biotech industry interviews Derek Jones, Chief Executive of Babraham Bioscience Technologies (BBT) to talk about strategies for biotech startups.

How to find the perfect venue for your next meeting

How to find the perfect venue for your next meeting

20/09/2017

Behind every successful meeting, lies the perfect venue. This can often be overlooked while you’re focussing on the smaller details of the day. If you’re responsible for coordinating your organisation’s next conference, or seminar, choosing the right space will be crucial to it's success.

Support for - The UK Life Science Strategy - ‘Making the UK the best place for life sciences businesses to grow’

Support for - The UK Life Science Strategy - ‘Making the UK the best place for life sciences businesses to grow’

30/08/2017

As part of the UK’s £64B life sciences sector Babraham Bioscience Technologies, (BBT), welcomes the publication of Prof. Sir John Bell’s Life Science Industrial Strategy to the UK Government.

CEGX and NuGEN Technologies Sign Partnership Agreement

CEGX and NuGEN Technologies Sign Partnership Agreement

15/08/2017

Cambridge Epigenetix (CEGX) and NuGEN Technologies, today announced that they have entered into a partnership agreement to integrate the CEGX TrueMethyl technology for oxidative bisulfite sequencing (oxBS-Seq) with NuGEN’s innovative NGS library preparation kits.

Bicycle Therapeutics Expands Leadership Team

Bicycle Therapeutics Expands Leadership Team

01/08/2017

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the appointment of Lee Kalowski as Chief Financial Officer.

PRESS ENQUIRIES

We are keen to promote the work that we do, telling the story of the Babraham Research Campus and the organisations that are based here. If you are interested in running a story, using our images or films or want to discuss an interview or potential collaboration opportunity we would be very pleased to hear from you.  Please contact Sarah at Limewash to discuss your requirements

Sarah Brereton, Director, Limewash
01223 813 557, info@limewash.co.uk
www.limewash.co.uk

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;